Previous close | 5.08 |
Open | 5.12 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 5.06 - 5.12 |
52-week range | 4.08 - 6.53 |
Volume | |
Avg. volume | 22,409 |
Market cap | 293.145M |
Beta (5Y monthly) | 0.24 |
PE ratio (TTM) | 34.00 |
EPS (TTM) | 0.15 |
Earnings date | 22 May 2024 - 27 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.00 |
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript March 6, 2024 Kamada Ltd. beats earnings expectations. Reported EPS is $0.09, expectations were $0.05. KMDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to Kamada Ltd.’s Fourth Quarter and […]
REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer. Dear Shareholders, Colleagues and Business Partners: The recently completed 2023 was another successful period in our com
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-YearStrong Momentum Supports Expected Double-Digit Growth with Anticipated Fiscal Year 2024 Revenues in Range of $156 to $160 Million and Expected Adjusted EBITDA in Range of $27 to $30 MillionKamada Maintains Financial Strength to Accelerate Growth and Pursue Compelling New Business Developm